Haemorrhage Alleviation With Tranexamic Acid- Intestinal System
Haemorrhage Alleviation With Tranexamic Acid- Intestinal System
Severe bleeding in the digestive system is a common symptom of many diseases. Each year,
 about 50,000 people end up in British hospitals because of this problem and about 5,000 of
 them die. The most common cause of this bleeding is stomach ulcers. In sub-Saharan Africa,
 schistosomiasis (parasitic worms) is responsible for about 130,000 deaths from stomach
 bleeding each year. From previous research in other bleeding conditions such as surgery and
 trauma, we know that a drug called tranexamic acid can reduce bleeding and save lives. We now
 want to do the HALT-IT trial to see if giving tranexamic acid can save lives and if there are
 any complications in people with severe bleeding from the digestive system.
BACKGROUND: Acute gastrointestinal (GI) haemorrhage is one of the most common
 gastrointestinal emergencies. It is an important cause of mortality and morbidity in high,
 middle and low income countries. The most common causes of upper GI haemorrhage are peptic
 ulcer, oesophageal varices and erosive mucosal disease, although the relative frequency of
 the different causes varies in different countries. Acute upper GI haemorrhage accounts for
 around 50,000 hospital admissions each year in the UK and has a case fatality of about 10%.
 The incidence is highest among the most disadvantaged social groups. Lower GI haemorrhage
 accounts for a further 15,000 hospital admissions each year and has a case fatality of
 between 10% and 20%. Upper GI haemorrhage is also a common medical emergency in low and
 middle income countries. Patients are usually young and poor and the source of bleeding is
 more often oesophageal varices. Fibrinolysis may play an important pathological role in GI
 haemorrhage due to premature breakdown of haemostatic plugs at sites of mucosal injury.
 Tranexamic acid (TXA) is a synthetic derivative of the amino acid lysine which inhibits
 fibrinolysis by blocking the lysine binding sites on plasminogen. It is a widely used
 treatment with a known safety profile. There is reliable evidence that TXA reduces blood
 transfusion in surgical patients. A systematic review including 65 trials shows that TXA
 reduces the probability of blood transfusion by 39% (RR=0.61, 95% CI 0.53 to 0.70) compared
 to control. The effect of TXA on the risk of thromboembolic events in surgical patients
 remains uncertain, although there is no evidence of any increase in risk. The CRASH-2 trial
 showed that administration of TXA significantly reduces deaths due to bleeding (RR=0.85, 95%
 CI 0.76 to 0.96), and all-cause mortality (RR=0.91, 95% CI 0.85 to 0.97) in trauma patients
 with significant extra-cranial bleeding, with no increase in vascular occlusive events. A
 systematic review conducted by the investigators of TXA in GI bleeding identified nine
 randomised trials including a total of 1721 patients. Although there was a statistically
 significant reduction in the risk of death in patients treated with TXA (RR=0.66, 95% CI 0.47
 to 0.93), the estimate is imprecise and the overall quality of trials was poor. Furthermore,
 all but three of the trials were conducted before the widespread use of therapeutic endoscopy
 and proton pump inhibitors and even in aggregate the trials were too small to assess the
 effects of TXA on other clinical important outcomes such as thromboembolic events. For these
 reasons, the effectiveness and safety of TXA for GI haemorrhage is uncertain and there are
 currently no formal recommendations for its use as a treatment for GI bleeding.

 AIM: The HALT-IT trial will determine the effect of TXA on mortality, morbidity (re-bleeding,
 non-fatal vascular events), blood transfusion, surgical intervention and health status in
 patients with acute gastrointestinal haemorrhage.

 PRIMARY OUTCOME: The primary outcome is death from haemorrhage within 5 days of randomisation
 (all cause and cause-specific mortality will also be recorded).

 SECONDARY OUTCOMES:

 1. Re-bleeding

 2. Endoscopic, radiological or surgical intervention

 3. Blood transfusion - blood or blood component units transfused

 4. Thromboembolic events (myocardial infarction, stroke, pulmonary embolism, deep vein
 thrombosis)

 5. Other adverse medical events (including renal failure, significant cardiac event,
 respiratory failure, hepatic failure, sepsis, pneumonia, seizure and other reported
 events)

 6. Functional status measured using the Katz Index of Independence in Activities of Daily
 Living

 7. Time spent at an intensive care unit

 8. Length of stay in hospital

 9. Patient status (death, hospital readmission) at 12 months will be ascertained if
 appropriate databases are available in the recruiting country

 TRIAL DESIGN:

 A pragmatic, randomised, double blind, placebo controlled trial among 12,000 patients with
 clinically significant gastrointestinal bleeding

 DIAGNOSIS AND INCLUSION/EXCLUSION CRITERIA:

 Adults with acute significant upper or lower gastrointestinal bleeding. The diagnosis of
 significant bleeding is clinical but may include patients with hypotension, tachycardia, or
 those likely to need transfusion, urgent endoscopy or surgery. The fundamental eligibility
 criterion is the responsible clinician's 'uncertainty' as to whether or not to use tranexamic
 acid in a particular patient with gastrointestinal bleeding. If the clinician believes there
 is a clear indication for, or clear contraindication to, tranexamic acid use, the particular
 patient should not be randomised. There are no other pre-specified exclusion criteria.

 TEST PRODUCT, REFERENCE THERAPY, DOSE AND MODE OF ADMINISTRATION:

 A loading dose of tranexamic acid (1 gram by intravenous injection) or placebo (sodium
 chloride 0.9%) will be given as soon as possible after randomisation followed by an
 intravenous infusion of 3 grams over 24 hours or placebo (sodium chloride 0.9%).

 SETTING:

 This trial will be coordinated from the London School of Hygiene & Tropical Medicine Clinical
 Trials Unit (University of London) and conducted in hospitals in low, middle and high income
 countries.

 DURATION OF TREATMENT AND PARTICIPATION:

 The first dose will be given immediately after randomisation and the maintenance dose will be
 given immediately after the loading dose over 24 hours. Participation will end at discharge
 from randomising hospital, death or at 28 days post randomisation whichever occurs first.

 CRITERIA FOR EVALUATION:

 All patients randomly assigned to one of the treatments will be analysed together (regardless
 of whether or not they completed or received that treatment) on an intention to treat basis.
Inclusion Criteria:

 -  adult patients

 -  with acute significant upper or lower gastrointestinal bleeding

 -  where the responsible clinician is substantially uncertain as to the appropriateness
 of antifibrinolytic agents in the patient

 Exclusion Criteria:

 -  The fundamental eligibility criterion is the responsible clinician's 'uncertainty' as
 to whether or not to use an antifibrinolytic agent in a particular patient with upper
 or lower gastrointestinal bleeding.

 -  There are no other exclusions.